Phase II Trial Explores Oral GLP-1 Agonist VCT220 for Obesity Treatment | Retatrutide News

A phase II trial is investigating VCT220, an oral nonpeptide GLP-1 receptor agonist, for obesity treatment. This development is significant for expandin...
Clinical Trials · October 10, 2026